These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12046683)

  • 21. Idiotype vaccines for human B-cell malignancies.
    Inoges S; de Cerio AL; Soria E; Villanueva H; Pastor F; Bendandi M
    Curr Pharm Des; 2010 Jan; 16(3):300-7. PubMed ID: 20109139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Escherichia coli-based production of a tumor idiotype antibody fragment--tetanus toxin fragment C fusion protein vaccine for B cell lymphoma.
    Patel KG; Ng PP; Levy S; Levy R; Swartz JR
    Protein Expr Purif; 2011 Jan; 75(1):15-20. PubMed ID: 20851769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toward personalized immunotherapy for non-Hodgkin lymphoma: targeting the idiotypic immunoglobulin.
    Armstrong AC; Cheadle EJ; Hawkins RE
    BioDrugs; 2005; 19(5):289-97. PubMed ID: 16207070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Idiotype vaccines in the treatment of follicular lymphoma: current status and future perspectives].
    Zabalegui N; López Díaz de Cerio A; Inogés S; Soria E; Villanueva H; Rivero P
    An Sist Sanit Navar; 2009; 32(1):61-73. PubMed ID: 19430512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
    Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
    Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor vaccination strategies combined with autologous peripheral stem cell transplantation.
    Kwak LW
    Ann Oncol; 1998; 9 Suppl 1():S41-6. PubMed ID: 9581240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
    Bendandi M; Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Pérez-Simón JA; Rodríguez-Caballero A; García-Montero A; Almeida J; Zabalegui N; Giraldo P; San Miguel J; Orfao A
    Leuk Lymphoma; 2006 Jan; 47(1):29-37. PubMed ID: 16321824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of human idiotype-specific T cells in lymphoma and myeloma.
    Weng J; Neelapu SS; Woo AF; Kwak LW
    Curr Top Microbiol Immunol; 2011; 344():193-210. PubMed ID: 20549471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA fusion vaccines against B-cell tumors.
    Zhu D; Rice J; Savelyeva N; Stevenson FK
    Trends Mol Med; 2001 Dec; 7(12):566-72. PubMed ID: 11733220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Active immunotherapy of multiple myeloma.
    Houet L; Veelken H
    Eur J Cancer; 2006 Jul; 42(11):1653-60. PubMed ID: 16797966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cells in clinical trials for multiple myeloma.
    Reichardt VL; Brossart P
    Methods Mol Med; 2005; 109():127-36. PubMed ID: 15585918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy using dendritic cells against multiple myeloma: how to improve?
    Nguyen-Pham TN; Lee YK; Kim HJ; Lee JJ
    Clin Dev Immunol; 2012; 2012():397648. PubMed ID: 22481968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.
    Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
    Clin Cancer Res; 2007 Mar; 13(5):1503-10. PubMed ID: 17332295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccines for lymphomas: idiotype vaccines and beyond.
    Houot R; Levy R
    Blood Rev; 2009 May; 23(3):137-42. PubMed ID: 18951668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients.
    Bergenbrant S; Yi Q; Osterborg A; Björkholm M; Osby E; Mellstedt H; Lefvert AK; Holm G
    Br J Haematol; 1996 Mar; 92(4):840-6. PubMed ID: 8616076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations.
    Büchler T; Hajek R
    Med Oncol; 2002; 19(4):213-8. PubMed ID: 12512914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current status of therapeutic vaccines for non-Hodgkin's lymphoma.
    Hurvitz SA; Timmerman JM
    Curr Opin Oncol; 2005 Sep; 17(5):432-40. PubMed ID: 16093791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Idiotype vaccination for lymphoma: moving towards optimisation.
    Houot R; Levy R
    Leuk Lymphoma; 2009 Jan; 50(1):1-2. PubMed ID: 19172492
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.